Prolutex in Frozen Embryo Transfer Cycles at the Blastocyst Stage (PROGEX)
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The objective of this proof of concept clinical trial is to evaluate the impact of two
different progesterone treatments for endometrial preparation (25 mg/twice-a-day,
subcutaneous injection, and 200 mg/three times a day, vaginal administration) on the clinical
pregnancy rate in women undergoing frozen embryo transfer (FET) at blastocyst stage.